UPDATE: Arcutis Biotherapeutics Reports Phase 1/2a ARQ-151 Data Showed Significant Improvement In Signs, Symptoms Of Chronic Plaque Psoriasis; Co. Sees Topline Data From Phase 3 Trial In H1'21